This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Revance Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Revance Therapeutics kazanç ve gelirinin sırasıyla yıllık 60.7% ve 19.2% oranında artması tahmin edilirken, EPS'nin yıllık 61% oranında büyümesi bekleniyor.

Anahtar bilgiler

60.7%

Kazanç büyüme oranı

60.98%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	14.5%
Gelir büyüme oranı	19.2%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	22 Jan 2025

Gelecekteki son büyüme güncellemeleri

Recent updates

Seeking Alpha • Sep 26

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Summary I initially downgraded Revance Therapeutics to a "Sell" in June due to financial struggles, competition, and potential cash flow issues by 2025. Revance's merger with Crown Labs at $6.66 per share, an 89% premium, temporarily boosted shares there are concerns surfacing about the deal's stability. The Teoxane dispute over RHA filler sales and marketing efforts could delay or jeopardize the merger, adding uncertainty to Revance's future. Despite potential positives, I maintain my "Sell" rating due to ongoing financial losses, competitive pressures, and merger uncertainties. Read the full article on Seeking Alpha

Seeking Alpha • Jun 20

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

Summary Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock price has fallen by nearly 70% year-to-date, facing financial vulnerability and market skepticism. Wall Street remains skeptical about Revance's business model and forecasts, given it is facing competitive threats and ongoing disputes, making recovery uncertain. The company is in a financially perilous position and faces litigation from AbbVie accusing the company of misappropriating trade secrets. On the one hand, there is a risky contrarian bet with Revance shares down >90% in 15 months, but I am siding with Wall Street - the company faces a fight to survive in the midst of so many issues. Read the full article on Seeking Alpha

Analiz Makalesi • Mar 04

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Those holding Revance Therapeutics, Inc. ( NASDAQ:RVNC ) shares would be relieved that the share price has rebounded...

Seeking Alpha • Feb 29

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Summary Revance Therapeutics, Inc. reported its Q4 and FY 23 earnings yesterday, February 28th - its stock price has been soaring as a result. The company is guiding for ~$280m of revenues in 2024 and narrowing losses - at least on a non-GAAP basis. I gave Revance stock a "sell" rating in my last note on the company at the end of November - I am upgrading my rating to Hold, for 2024. The company still faces major long term obstacles to success in my view, but management remains bullish and there are reasons to be more optimistic for 2024. Read the full article on Seeking Alpha

Analiz Makalesi • Dec 28

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

Revance Therapeutics, Inc. ( NASDAQ:RVNC ) shareholders are no doubt pleased to see that the share price has bounced...

Analiz Makalesi • Nov 10

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

The analysts covering Revance Therapeutics, Inc. ( NASDAQ:RVNC ) delivered a dose of negativity to shareholders today...

Analiz Makalesi • Aug 10

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Analiz Makalesi • Jun 14

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

When you see that almost half of the companies in the Pharmaceuticals industry in the United States have price-to-sales...

Analiz Makalesi • Apr 17

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...

Analiz Makalesi • Jan 02

Revance Therapeutics (NASDAQ:RVNC) Is Making Moderate Use Of Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:RVNC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2027	497	-9	131	85	5
12/31/2026	415	-31	55	26	8
12/31/2025	333	-102	-35	-24	8
12/31/2024	264	-168	-108	-53	8
9/30/2024	257	-303	-195	-191	N/A
6/30/2024	251	-304	-209	-201	N/A
3/31/2024	240	-325	-221	-213	N/A
12/31/2023	234	-324	-223	-217	N/A
9/30/2023	204	-292	-210	-204	N/A
6/30/2023	179	-337	-214	-211	N/A
3/31/2023	153	-341	-204	-202	N/A
12/31/2022	133	-356	-197	-194	N/A
9/30/2022	109	-274	-214	-208	N/A
6/30/2022	99	-263	-210	-203	N/A
3/31/2022	90	-274	-216	-208	N/A
12/31/2021	78	-281	-232	-222	N/A
9/30/2021	63	-297	-247	-239	N/A
6/30/2021	47	-303	-250	-242	N/A
3/31/2021	29	-292	-218	-210	N/A
12/31/2020	15	-282	-183	-179	N/A
9/30/2020	4	-249	-152	-150	N/A
6/30/2020	0	-209	-129	-126	N/A
3/31/2020	0	-186	-141	-138	N/A
12/31/2019	0	-159	-109	-106	N/A
9/30/2019	1	-155	-108	-104	N/A
6/30/2019	3	-146	-103	-97	N/A
3/31/2019	4	-143	-112	-105	N/A
12/31/2018	4	-143	-111	-104	N/A
9/30/2018	3	-138	-107	-102	N/A
6/30/2018	1	-136	N/A	-98	N/A
3/31/2018	0	-128	N/A	-85	N/A
12/31/2017	0	-121	N/A	-95	N/A
9/30/2017	0	-111	N/A	-80	N/A
6/30/2017	0	-99	N/A	-73	N/A
3/31/2017	0	-97	N/A	-65	N/A
12/31/2016	0	-89	N/A	-60	N/A
9/30/2016	0	-85	N/A	-63	N/A
6/30/2016	0	-86	N/A	-62	N/A
3/31/2016	0	-78	N/A	-58	N/A
12/31/2015	0	-73	N/A	-56	N/A
9/30/2015	0	-66	N/A	-48	N/A
6/30/2015	0	-60	N/A	-47	N/A
3/31/2015	0	-57	N/A	-47	N/A
12/31/2014	0	-63	N/A	-55	N/A
9/30/2014	1	-49	N/A	-60	N/A
6/30/2014	1	-48	N/A	-54	N/A
3/31/2014	1	-38	N/A	-62	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: RVNC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: RVNC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: RVNC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: RVNC şirketinin gelirinin (yıllık 19.2% ) US pazarından (yıllık 11.7% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: RVNC şirketinin gelirinin (yıllık 19.2% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: RVNC 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/02/05 06:51
Gün Sonu Hisse Fiyatı	2025/02/05 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Revance Therapeutics, Inc. 10 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
David Maris	BMO Capital Markets Equity Research
Louise Chen	Cantor Fitzgerald & Co.
Donald Ellis	Citizens JMP Securities, LLC

This company has been acquired

Revance Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 1/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Price target decreased by 17% to US$13.58

Forecast to breakeven in 2026

Price target decreased by 18% to US$16.33

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Recent updates

Revance Therapeutics Common Stock to Delist from Nasdaq Global Select Market

Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from NASDAQ Composite Index

Crown Laboratories, Inc. completed the acquisition of Revance Therapeutics, Inc. (NasdaqGM:RVNC).

Revance Therapeutics, Inc.(NasdaqGM:RVNC) dropped from NASDAQ Biotechnology Index

Teoxane S.A. cancelled the acquisition to acquire all remaining stake in Revance Therapeutics, Inc. (NasdaqGM:RVNC).

Teoxane S.A. submitted a proposal to acquire all remaining stake in Revance Therapeutics, Inc. (NasdaqGM:RVNC) for $360 million.

Holzer & Holzer, Llc Files Class Action Lawsuit Against Revance Therapeutics, Inc

Revance Therapeutics: Crown Merger Red Flags Makes For Problematic Call On Shares

Crown Laboratories, Inc. entered into a merger agreement to acquire Revance Therapeutics, Inc. (NasdaqGM:RVNC) for approximately $720 million.

Revance Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Revance Therapeutics: Problems Mounting Amid Legal And Financial Woes

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 17% to US$13.58

Revance Therapeutics, Inc. Announces the Commercial Launch of DAXXIFY (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Revance Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Forecast to breakeven in 2026

Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting

Insufficient new directors

Revance Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

What Revance Therapeutics, Inc.'s (NASDAQ:RVNC) 30% Share Price Gain Is Not Telling You

Revance Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Price target decreased by 18% to US$16.33

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Revance: Stock Bouncing On Q4 Earnings, But Long-Term Challenges Remain

Revance Therapeutics, Inc. Announces Executive Changes

Revance Therapeutics, Inc. Receives Permanent J-Code for DAXXIFY and Announces Publication of Daxify Pivotal Study (ASPEN-1) Results in Neurology

Price target decreased by 14% to US$23.17

Price target decreased by 9.9% to US$25.67

Revenues Not Telling The Story For Revance Therapeutics, Inc. (NASDAQ:RVNC) After Shares Rise 27%

New minor risk - Profitability

Revance Therapeutics, Inc. Reports Consolidated Impairment for the Quarter Ended September 30, 2023

Analysts Are More Bearish On Revance Therapeutics, Inc. (NASDAQ:RVNC) Than They Used To Be

Price target decreased by 18% to US$29.25

Revance Therapeutics, Inc. Appoints Erica Jordan as Senior Vice President of Commercial to Chief Commercial Officer, Aesthetics

Price target decreased by 7.1% to US$33.67

Revance Therapeutics, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Price target decreased by 9.0% to US$36.25

Consensus EPS estimates fall by 13%

Senior VP notifies of intention to sell stock

U.S. FDA Approves First Therapeutic Indication for Revance's Daxxify (Daxibotulinumtoxina-Lanm) for Injection for the Treatment of Cervical Dystonia

Here's Why Revance Therapeutics (NASDAQ:RVNC) Can Afford Some Debt

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

CEO & Director notifies of intention to sell stock

Revance Therapeutics, Inc.'s (NASDAQ:RVNC) Earnings Haven't Escaped The Attention Of Investors

CEO & Director notifies of intention to sell stock

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.4m worth of stock

Forecast to breakeven in 2025

CEO & Director notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

CFO & Principal Accounting Officer notifies of intention to sell stock

Does Revance Therapeutics (NASDAQ:RVNC) Have A Healthy Balance Sheet?

CFO & Principal Accounting Officer notifies of intention to sell stock

CEO & Director recently sold US$2.2m worth of stock

No longer forecast to breakeven

CEO & Director notifies of intention to sell stock

Consensus estimates of losses per share improve by 12%

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

CFO & Principal Accounting Officer notifies of intention to sell stock

Forecast to breakeven in 2025

CFO & Principal Accounting Officer notifies of intention to sell stock